Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768634 | 0.90 | ADORA2A (0.35) | SLC6A4HRH3DRD2DRD4DRD3 | |
| SCHEMBL14768626 | 0.88 | ELANE (0.42) | USP2CYP2D6SMN1; SMN2SLC6A4HRH3 | |
| SCHEMBL14768628 | 0.87 | LMNA (0.40) | USP2CYP2D6SMN1; SMN2ELANEGRM2 | |
| SCHEMBL14768596 | 0.85 | L3MBTL1 (0.38) | SMN1; SMN2DRD2DRD4DRD3ADORA1 | |
| SCHEMBL15334533 | 0.83 | DDR1 (0.31) | — | |
| SCHEMBL14768619 | 0.79 | CHRNA7 (0.43) | HRH3DRD2DRD4DRD3 | |
| SCHEMBL14768592 | 0.77 | CYP2A13 (0.40) | SLC6A4HRH3DRD2DRD4DRD3 | |
| SCHEMBL14768590 | 0.76 | ACHE (0.41) | SMN1; SMN2HRH3ACHEDRD2DRD4 | |
| SCHEMBL14768599 | 0.75 | KMT2A (0.41) | SMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL14768607 | 0.74 | CHRNA7 (0.39) | SMN1; SMN2HRH3DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8563544-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | USP2 1284/4885CYP2D6 2157/4885SMN1; SMN2 603/4885 |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | USP2 1284/4885CYP2D6 2157/4885SMN1; SMN2 603/4885 |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | USP2 1284/4885CYP2D6 2157/4885SMN1; SMN2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.